Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Anixa Biosciences (NASDAQ: ANIX) announced that CEO Dr. Amit Kumar will present at the 2025 CAGLA NeauxCancer Conference on March 28th, 2025, at 10:00 AM CDT in New Orleans. The presentation, taking place at The Roosevelt Hotel, will showcase Anixa's innovative cancer treatment programs.
Dr. Kumar will provide updates on the company's cutting-edge CAR-T therapy for solid tumors and novel cancer vaccine initiatives. The presentation will highlight Anixa's progress in clinical development and their approach to advancing next-generation immunotherapies in cancer care.
The CAGLA NeauxCancer Conference, scheduled for March 27-29, 2025, brings together oncology researchers, industry executives, investors, and medical professionals to discuss breakthrough developments in cancer treatment.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato che il CEO Dr. Amit Kumar presenterà al 2025 CAGLA NeauxCancer Conference il 28 marzo 2025, alle 10:00 AM CDT a New Orleans. La presentazione, che si terrà presso il The Roosevelt Hotel, metterà in mostra i programmi innovativi di trattamento del cancro di Anixa.
Il Dr. Kumar fornirà aggiornamenti sulla terapia CAR-T all'avanguardia per i tumori solidi e sulle nuove iniziative di vaccini contro il cancro. La presentazione evidenzierà i progressi di Anixa nello sviluppo clinico e il loro approccio per promuovere le immunoterapie di nuova generazione nella cura del cancro.
Il CAGLA NeauxCancer Conference, programmato dal 27 al 29 marzo 2025, riunisce ricercatori oncologici, dirigenti del settore, investitori e professionisti medici per discutere i progressi rivoluzionari nel trattamento del cancro.
Anixa Biosciences (NASDAQ: ANIX) anunció que el CEO Dr. Amit Kumar presentará en la 2025 CAGLA NeauxCancer Conference el 28 de marzo de 2025, a las 10:00 AM CDT en Nueva Orleans. La presentación, que se llevará a cabo en el The Roosevelt Hotel, mostrará los programas innovadores de tratamiento del cáncer de Anixa.
El Dr. Kumar proporcionará actualizaciones sobre la terapia CAR-T de vanguardia para tumores sólidos y las nuevas iniciativas de vacunas contra el cáncer. La presentación destacará los avances de Anixa en el desarrollo clínico y su enfoque para avanzar en las inmunoterapias de próxima generación en el cuidado del cáncer.
La CAGLA NeauxCancer Conference, programada del 27 al 29 de marzo de 2025, reúne a investigadores en oncología, ejecutivos de la industria, inversores y profesionales médicos para discutir desarrollos innovadores en el tratamiento del cáncer.
Anixa Biosciences (NASDAQ: ANIX)는 CEO Dr. Amit Kumar가 2025년 3월 28일 오전 10시 CDT에 뉴올리언스의 2025 CAGLA NeauxCancer Conference에서 발표할 것이라고 발표했습니다. 발표는 The Roosevelt Hotel에서 열리며 Anixa의 혁신적인 암 치료 프로그램을 소개할 것입니다.
Dr. Kumar는 고형 종양을 위한 최첨단 CAR-T 치료법과 새로운 암 백신 이니셔티브에 대한 업데이트를 제공할 것입니다. 발표에서는 Anixa의 임상 개발 진행 상황과 암 치료에서 차세대 면역 요법을 발전시키기 위한 접근 방식을 강조할 것입니다.
2025년 3월 27일부터 29일까지 예정된 CAGLA NeauxCancer Conference는 종양학 연구원, 산업 경영진, 투자자 및 의료 전문가들이 모여 암 치료의 혁신적인 발전에 대해 논의하는 자리입니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé que le PDG Dr. Amit Kumar présentera à la 2025 CAGLA NeauxCancer Conference le 28 mars 2025 à 10h00 CDT à La Nouvelle-Orléans. La présentation, qui se déroulera à l'hôtel Roosevelt, mettra en avant les programmes innovants de traitement du cancer d'Anixa.
Le Dr. Kumar fournira des mises à jour sur la thérapie CAR-T de pointe pour les tumeurs solides et les nouvelles initiatives de vaccins contre le cancer. La présentation mettra en lumière les progrès d'Anixa dans le développement clinique et leur approche pour faire avancer les immunothérapies de nouvelle génération dans les soins du cancer.
La CAGLA NeauxCancer Conference, prévue du 27 au 29 mars 2025, rassemble des chercheurs en oncologie, des dirigeants de l'industrie, des investisseurs et des professionnels de la santé pour discuter des développements révolutionnaires dans le traitement du cancer.
Anixa Biosciences (NASDAQ: ANIX) gab bekannt, dass CEO Dr. Amit Kumar am 28. März 2025 um 10:00 Uhr CDT auf der 2025 CAGLA NeauxCancer Conference in New Orleans präsentieren wird. Die Präsentation, die im The Roosevelt Hotel stattfindet, wird die innovativen Krebsbehandlungsprogramme von Anixa vorstellen.
Dr. Kumar wird Updates zur modernsten CAR-T-Therapie für solide Tumoren und zu neuartigen Impfstoffinitiativen gegen Krebs geben. Die Präsentation wird die Fortschritte von Anixa in der klinischen Entwicklung und ihren Ansatz zur Förderung von Immuntherapien der nächsten Generation in der Krebsbehandlung hervorheben.
Die CAGLA NeauxCancer Conference, die vom 27. bis 29. März 2025 stattfindet, bringt Onkologieforscher, Führungskräfte der Branche, Investoren und medizinische Fachkräfte zusammen, um bahnbrechende Entwicklungen in der Krebsbehandlung zu diskutieren.
- None.
- None.
Dr. Kumar's presentation will provide an overview of Anixa's pioneering programs in cancer treatment, including updates on its cutting-edge CAR-T therapy for solid tumors and its novel cancer vaccine initiatives. He will discuss the Company's latest progress in clinical development and how Anixa is advancing next-generation immunotherapies to transform cancer care.
Details of the presentation are as follows:
Event: 2025 CAGLA NeauxCancer Conference
Date: March 28, 2025
Time: 10:00 AM CDT
Location: The Roosevelt New Orleans
Webcast: CAGLA 2025 Livestreams
The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, industry executives, investors and medical professionals focused on groundbreaking developments in cancer treatment and care.
For more information about the conference, visit https://cag-la.org/neauxcancer-2025/.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ceo-to-present-at-the-2025-cagla-neauxcancer-conference-on-march-28th-302401546.html
SOURCE Anixa Biosciences, Inc.